144 related articles for article (PubMed ID: 17499401)
1. Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2007 Jun; 25(25):4809-17. PubMed ID: 17499401
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
[TBL] [Abstract][Full Text] [Related]
4. "Recreational" drug abuse associated with failure to mount a proper antibody response after a generalised orthopoxvirus infection.
Huemer HP; Himmelreich A; Hönlinger B; Pavlic M; Eisendle K; Höpfl R; Rabl W; Czerny CP
Infection; 2007 Dec; 35(6):469-73. PubMed ID: 17917699
[TBL] [Abstract][Full Text] [Related]
5. The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice.
MacNeill AL; Moldawer LL; Moyer RW
Virology; 2009 Feb; 384(1):151-60. PubMed ID: 19056101
[TBL] [Abstract][Full Text] [Related]
6. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
7. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.
Melamed S; Paran N; Katz L; Ben-Nathan D; Israely T; Schneider P; Levin R; Lustig S
Vaccine; 2007 Nov; 25(45):7743-53. PubMed ID: 17928110
[TBL] [Abstract][Full Text] [Related]
8. Obligatory requirement for antibody in recovery from a primary poxvirus infection.
Chaudhri G; Panchanathan V; Bluethmann H; Karupiah G
J Virol; 2006 Jul; 80(13):6339-44. PubMed ID: 16775322
[TBL] [Abstract][Full Text] [Related]
9. Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis.
Miller CG; Justus DE; Jayaraman S; Kotwal GJ
Cell Immunol; 1995 May; 162(2):326-32. PubMed ID: 7743560
[TBL] [Abstract][Full Text] [Related]
10. Atypical Cowpox Virus Infection in Smallpox-Vaccinated Patient, France.
Andreani J; Arnault JP; Bou Khalil JY; Abrahão J; Tomei E; Vial E; Le Bideau M; Raoult D; La Scola B
Emerg Infect Dis; 2019 Feb; 25(2):212-219. PubMed ID: 30666929
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids lead to enhanced virulence of the smallpox vaccine (vaccinia) virus.
Huemer HP; Lassnig C; Bernhard D; Sturm S; Nowotny N; Kitchen M; Pavlic M
Immunobiology; 2011 Jun; 216(6):670-7. PubMed ID: 21131094
[TBL] [Abstract][Full Text] [Related]
12. Adaptive Immune Response to Vaccinia Virus LIVP Infection of BALB/c Mice and Protection against Lethal Reinfection with Cowpox Virus.
Shchelkunov SN; Sergeev AA; Yakubitskiy SN; Titova KA; Pyankov SA; Kolosova IV; Starostina EV; Borgoyakova MB; Zadorozhny AM; Kisakov DN; Shulgina IS; Karpenko LI
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452494
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
14. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
[TBL] [Abstract][Full Text] [Related]
15. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
16. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Stittelaar KJ; Neyts J; Naesens L; van Amerongen G; van Lavieren RF; Holý A; De Clercq E; Niesters HG; Fries E; Maas C; Mulder PG; van der Zeijst BA; Osterhaus AD
Nature; 2006 Feb; 439(7077):745-8. PubMed ID: 16341204
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
18. Clinical course and pathology in rats (Rattus norvegicus) after experimental cowpox virus infection by percutaneous and intranasal application.
Breithaupt A; Kalthoff D; Deutskens F; König P; Hoffmann B; Beer M; Meyer H; Teifke JP
Vet Pathol; 2012 Nov; 49(6):941-9. PubMed ID: 22411549
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of smallpox vaccines prepared from strains of different reactogenicity.
Nyerges G; Csukás M
Acta Microbiol Acad Sci Hung; 1972; 19(2):103-9. PubMed ID: 4670218
[No Abstract] [Full Text] [Related]
20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
